Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.220
-0.010 (-0.31%)
At close: Nov 4, 2024, 4:00 PM
3.230
+0.010 (0.31%)
After-hours: Nov 4, 2024, 5:30 PM EST

Xeris Biopharma Holdings Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2016
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2016
Market Capitalization
480325181365--
Upgrade
Market Cap Growth
-7.28%79.47%-50.50%---
Upgrade
Enterprise Value
672487226360--
Upgrade
Last Close Price
3.222.351.332.93--
Upgrade
PE Ratio
--5.20-1.91-1.89--
Upgrade
PS Ratio
2.511.981.647.37--
Upgrade
PB Ratio
-17.30-47.864.003.84--
Upgrade
P/FCF Ratio
-8.59-6.59-1.75-3.78--
Upgrade
P/OCF Ratio
-8.83-6.90-1.76-3.82--
Upgrade
EV/Sales Ratio
3.702.972.057.26--
Upgrade
EV/EBITDA Ratio
-20.60-15.36-3.31-3.48--
Upgrade
EV/EBIT Ratio
-13.85-11.06-2.81-3.41--
Upgrade
EV/FCF Ratio
-13.26-9.87-2.18-3.73--
Upgrade
Debt / Equity Ratio
-13.99-33.794.380.922.584.04
Upgrade
Debt / FCF Ratio
-6.95-4.65-1.92-0.91-1.08-0.55
Upgrade
Asset Turnover
0.550.490.340.210.150.02
Upgrade
Inventory Turnover
0.740.901.061.011.77-
Upgrade
Quick Ratio
1.591.172.081.524.992.94
Upgrade
Current Ratio
2.261.642.541.805.403.20
Upgrade
Return on Equity (ROE)
--324.20%-134.83%-190.28%-378.20%-279.56%
Upgrade
Return on Assets (ROA)
-7.04%-8.25%-15.50%-28.45%-38.01%-66.80%
Upgrade
Return on Capital (ROIC)
-9.50%-11.81%-23.58%-43.37%-52.67%-84.97%
Upgrade
Earnings Yield
-12.41%-19.18%-52.34%-33.59%--
Upgrade
FCF Yield
-8.09%-15.18%-57.18%-26.44%--
Upgrade
Buyback Yield / Dilution
-3.38%-1.51%-71.62%-85.32%-63.32%-116.75%
Upgrade
Total Shareholder Return
-3.38%-1.51%-71.62%-85.32%-63.32%-116.75%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.